Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cipla
Citi
Federal Trade Commission
Cantor Fitzgerald
US Department of Justice
Healthtrust
Boehringer Ingelheim
Accenture

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018240

« Back to Dashboard

NDA 018240 describes TENORMIN, which is a drug marketed by Astrazeneca and Alvogen Malta and is included in two NDAs. It is available from two suppliers. Additional details are available on the TENORMIN profile page.

The generic ingredient in TENORMIN is atenolol. There are thirty-three drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the atenolol profile page.
Summary for 018240
Tradename:TENORMIN
Applicant:Alvogen Malta
Ingredient:atenolol
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 018240
Mechanism of ActionAdrenergic beta-Antagonists
Suppliers and Packaging for NDA: 018240
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TENORMIN atenolol TABLET;ORAL 018240 NDA AstraZeneca Pharmaceuticals LP 0310-0101 N 0310-0101-10
TENORMIN atenolol TABLET;ORAL 018240 NDA AstraZeneca Pharmaceuticals LP 0310-0105 N 0310-0105-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:Apr 9, 1990TE:ABRLD:Yes

Expired US Patents for NDA 018240

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen Malta TENORMIN atenolol TABLET;ORAL 018240-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Alvogen Malta TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Alvogen Malta TENORMIN atenolol TABLET;ORAL 018240-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Alvogen Malta TENORMIN atenolol TABLET;ORAL 018240-004 Apr 9, 1990 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKinsey
Baxter
Johnson and Johnson
Covington
QuintilesIMS
US Army
US Department of Justice
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.